Pharmacological action Estring (Estradiol Vaginal Ring)
Estring. Follicular hormone needed for the development of the female body and reproductive system. Exogenous estradiol has the same physiological effect as the natural hormone: stimulates the development of the uterus, fallopian tubes, the development of secondary sexual characteristics in their underdevelopment, causes proliferative changes in the endometrium, increases the excitability of the uterus, in large doses suppresses lactation. Estradiol regulates nitrogen metabolism, lowers blood lipid levels and cholesterol levels, has a weak anabolic effect. It promotes a balance between osteoblasts and osteoclasts, reducing bone resorption and promotes its formation.
Pharmacokinetics Estring (Estradiol Vaginal Ring)
After oral administration, absorbed from the gastrointestinal tract. Subjected to the effect of “first pass” through the liver. Metabolized to less active metabolites – estriol and estrone. Metabolites excreted by the kidneys, a small part – through the intestines.
Statement Estring (Estradiol Vaginal Ring)
Primary and secondary amenorrhea, hypoplastic genitalia and secondary sexual characteristics, disorders, hormone replacement therapy observed during a natural or surgically induced menopause (including vasomotor disturbances, hot flushes, sweating, sleep disturbances, atrophic processes of the vagina and lower urinary tract infection) caused by a deficiency of endogenous estrogen production, prevention of recurrent infectious and inflammatory diseases of the vagina and lower urinary tract, prevention and treatment of postmenopausal osteoporosis.
Dosage regimen Estring (Estradiol Vaginal Ring)
Individual, depending on the indications and dosage form used.
Treatment by estradiol supplemented with gestagen therapy for at least 10 days (1 every 1-3 months).
Side effect Estring (Estradiol Vaginal Ring)
Central nervous system: possible headache, dizziness, depression.
Part of the digestive system: nausea, vomiting, cholestatic jaundice, hepatic dysfunction, formation of stones in the gallbladder.
Part of the endocrine system: uterine and vaginal bleeding, tension in the mammary glands and their increase, changes in libido, endometrial proliferation, endometrial carcinoma development (in women with an intact uterus after menopause), edema, weight gain.
Allergic reactions: possible hives, skin rash.
Dermatological reactions: possible erythema multiforme, chloasma, melasma.
Contraindications Estring (Estradiol Vaginal Ring)
Breast cancer and endometrial cancer, uterine cancer, endometriosis, uterine bleeding of unknown cause, severe liver disease, severe cardiovascular disease, collagen disease, porphyria, pituitary tumors, otosclerosis, thrombophlebitis, thromboembolism, pregnancy, lactation (breastfeeding); guidance history of hepatitis, jaundice, prolonged itching, herpes during the previous pregnancy.
Pregnancy and breastfeeding Estring (Estradiol Vaginal Ring)
Contraindicated during pregnancy and lactation.
Cautions
Before treatment is necessary to conduct a gynecological examination, and long-term therapy – at least 1 times a year. Estradiol treatment appropriate to combine with gestagen therapy.
Caution should be used in patients with coronary heart disease, circulatory failure, migraine, asthma, epilepsy, severe hypertension, impaired liver and / or kidneys.
Estradiol can increase the available uterine fibroids.
During the period of estradiol should be systematically monitoring of liver function and blood pressure, blood glucose concentrations in diabetes mellitus.
Drug Interactions
Estrogens may decrease effects of anticoagulants, antihypertensive and hypoglycemic drugs.
With simultaneous application of estradiol and drugs that induce hepatic enzymes (barbiturates, carbamazepine, griseofulvin, and rifampin) may decrease the level of estradiol in the blood plasma.
